The use of estradiol heptanoate (Progynon Depot) should strictly follow the principle of individualization, involving various precautions such as administration methods, monitoring points, and management of special populations. The following provides a systematic explanation of key precautions from the perspectives of medication usage standards, prevention of adverse reactions, and contraindication management.

1. Technical specifications for drug administration

(1) Injection method: limited to deep muscle injection only. It is recommended to alternate injections into the gluteus maximus muscle to avoid local hardening formation. Before injection, draw back to confirm no blood return to prevent accidental injection into the blood vessel.

(2) Injection cycle: The routine injection is once every 4 weeks, which can be shortened to 2-3 weeks for perimenopausal patients. Medication must be administered strictly on time, and any missed doses must be promptly replenished upon recollection, but cannot be compensated with double the dosage.

2. Medication monitoring requirements

(1) Endometrial monitoring: Long term medication users need to undergo vaginal ultrasound examination every 6 months. When the endometrial thickness is greater than 5mm, progesterone or biopsy may be considered.

(2) Metabolic indicators: blood lipids and blood glucose were measured at baseline and 6 months after drug administration. diabetes patients need to strengthen the frequency of blood glucose monitoring.

(3) Liver function: After the first month of medication, the transaminase should be rechecked. If jaundice and itching occur, the medication should be stopped immediately for evaluation.

3. Adverse reaction response

(1) Thrombosis prevention: Evaluate personal and family history of thrombosis before medication, and seek emergency medical attention if there is lower limb swelling, pain, or difficulty breathing.

(2) Allergy treatment: Observe for 30 minutes after injection, and immediately rescue with adrenaline if rash and laryngeal edema occur.

(3) Breast symptoms: New lumps or persistent swelling and pain require breast ultrasound examination, and medication may be suspended if necessary.

4. Management of special populations

(1) Liver and kidney dysfunction: Patients with Child Pugh B grade or eGFR<30ml/min should reduce their dosage by 50% and dialysis should be avoided.

(2) Adolescent patients with Turner syndrome and other conditions should be used under the guidance of pediatric endocrinologists and in conjunction with bone age monitoring.

(3) High risk group of breast cancer: BRCA mutation carriers are forbidden. Survivors of hormone independent cancer need consultation in oncology department.

5. Contraindications warning

(1) Absolute contraindications: active thrombosis, estrogen dependent tumors, unexplained vaginal bleeding, and severe liver disease.

(2) Relative contraindications: Migraine with premonitory symptoms, gallbladder disease, and hypertriglyceridemia (>500mg/dl) should be weighed for their pros and cons.

6. Drug interactions

(1) CYP3A4 inducer: If rifampicin can reduce blood drug concentration by more than 50%, the dosage needs to be adjusted.

(2) Anticoagulants: Enhance the efficacy of warfarin, and INR should be monitored weekly when used in combination.

(3) Thyroid hormones: may increase hormone binding globulin, and free T4 levels need to be monitored.